ArticleBiomedicine hub
Differential Expression of Micro-RNA in Maternal Blood of Pregnancies Affected with Late-Onset Fetal Growth Restriction.
Article in Biomedicine hub. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Micro-RNAs (miRNAs) participate in different biological processes, including fetal hypoxia. In this work, we aimed to evaluate the existence of a miRNA differential expression profile in maternal blood of pregnancies affected with late-onset fetal growth restriction (LO-FGR). Methods: In a prospective study, a group of 35 fetuses were evaluated with Doppler ultrasound after 36 weeks. These included 15 fetuses with LO-FGR defined as fetal birth weight <10th centile plus a cerebroplacental ratio (CPR) <0.6765 MoM and 20 normal fetuses (normal BW plus a normal CPR). Afterward, for every pregnancy, maternal blood plasma was collected at birth, miRNAs were extracted, and full miRNA sequencing was performed using 20 of the indicated samples (12 with LO-FGR and 8 normal), determining the existence of differentially expressed miRNAs. Finally, this differential expression was validated in a wider population of 35 fetuses by means of quantitative reverse transcription polymerase chain reaction. Results: Full mRNA sequencing showed that FGR mothers expressed differential expression of several miRNA. The highest differences were seen for miR-486-5p/3p, miR-516a/b-5p, miR-19a/b-3p, miR-296-5p, miR-10b-5p, miR-205-5p, and Let-7g-5p. However, PCR validation only confirmed significant differences in miR-486-5p/3p. Conclusion: Mothers delivering FGR fetuses express a miRNA profile, which includes differential expression of miR-486-5p/3p. This information might improve our understanding of the pathophysiological processes involved in late-onset FGR. Future validation and feasibility studies will be required to propose maternal blood miRNAs as a valid tool in the diagnosis and management of FGR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.